Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XXVI: Antiplatelet and antithrombotic effects of the oligoamine RE 1492 in combination with standard and future antithrombotic drugs.
The combined effects of the oligoamine RE 1492 with the NO-donor RE 2047 or ASA, ticlopidine, pentoxifylline and BM 14515 were determined in vitro (Born-test) and in vivo (rat thrombosis model). The effects in vitro were supra additive but over independent. In vivo all combinations showed over additive and over independent inhibition of thrombus formation. The best results were obtained with a combination of 10 mg/kg RE 1492C and 10 mg/kg RE 2047. It inhibited thrombus formation in arterioles (A) by 79% and 36% in venoles (V). The combined effect of RE 1492C and pentoxifylline 10 mg/kg each was 62% (A) or 32% (V), respectively.
Rehse
K
K
Institut für Pharmazie, Freien Universität Berlin.
Ciborski
T
T
D000818:Animals; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011073:Polyamines / Q000494:pharmacology*; D051381:Rats
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D011073:Polyamines; C067017:RE 1492